MIR30E

Summary

MIR30E (microRNA 30e, HGNC:31629) is a microRNA gene on chromosome 1p34.2.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 407034 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31629
Approved symbol	MIR30E
Name	microRNA 30e
Location	1p34.2
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-30e
Ensembl gene	ENSG00000198974
Ensembl biotype	miRNA
OMIM	619105
Entrez	407034
RNAcentral	URS000075C4DE — miRNA, 92 nt, 33 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000362104

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000362104 — 1 exons

Exon	Start	End
ENSE00001436867	40754355	40754446

Expression profiles

Bgee: expression breadth broad, 65 present calls, max score 85.59.

Top tissues by expression

65 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	85.59	gold quality
monocyte	CL:0000576	78.74	gold quality
calcaneal tendon	UBERON:0003701	77.14	gold quality
lung	UBERON:0002048	76.14	gold quality
muscle of leg	UBERON:0001383	75.97	gold quality
stomach	UBERON:0000945	75.37	gold quality
adrenal tissue	UBERON:0018303	75.11	gold quality
gastrocnemius	UBERON:0001388	74.24	gold quality
multicellular organism	UBERON:0000468	73.80	gold quality
intestine	UBERON:0000160	73.27	gold quality
kidney	UBERON:0002113	73.10	gold quality
colon	UBERON:0001155	72.96	gold quality
adult mammalian kidney	UBERON:0000082	72.78	gold quality
heart	UBERON:0000948	72.73	gold quality
right atrium auricular region	UBERON:0006631	72.50	gold quality
liver	UBERON:0002107	71.49	gold quality
body of pancreas	UBERON:0001150	70.31	gold quality
renal glomerulus	UBERON:0000074	69.74	gold quality
ascending aorta	UBERON:0001496	69.62	gold quality
right lobe of liver	UBERON:0001114	69.36	gold quality
thoracic aorta	UBERON:0001515	69.27	gold quality
left adrenal gland	UBERON:0001234	69.10	gold quality
caudate nucleus	UBERON:0001873	69.09	gold quality
nucleus accumbens	UBERON:0001882	69.04	gold quality
esophagus mucosa	UBERON:0002469	69.00	gold quality
muscle layer of sigmoid colon	UBERON:0035805	68.99	gold quality
lower esophagus	UBERON:0013473	68.75	gold quality
myometrium	UBERON:0001296	68.73	gold quality
endometrium	UBERON:0001295	68.65	gold quality
lower esophagus muscularis layer	UBERON:0035833	68.43	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.43

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CTNNB1

Literature-anchored findings (GeneRIF, showing 40)

• Data show that further evaluation of miR-30e and miR-16-2 as prognostic biomarkers is warranted in patients with esophageal adenocarcinoma. (PMID:20309880)
• We identified a new potentially functional variant ss178077483 located in the pre-mir-30e, which was strongly associated with schizophrenia (allelic P=0.00017; genotypic P=0.00015), with an odds ratio of 4.952 (95% confidence interval: 1.887-12.998). (PMID:20347265)
• To our knowledge, this is the first evidence to suggest that miRNA polymorphisms may play an important role in MDD susceptibility. These findings also imply that certain miRNAs may be involved in the etiology of MDD. (PMID:20579744)
• miR-30e* was found to be upregulated in primary human glioma cells and correlated with malignant progression and poor survival. (PMID:22156201)
• Two abundant miRNAs, miR-30e and miR-378, are markedly decreased by IFN-alpha in activated natural killer (NK) cells. (PMID:22649192)
• This case-control study provides supportive evidence for the contribution of rs112439044 in MIR30E to schizophrenia susceptibility. (PMID:24025694)
• findings suggest that TAMs may cause increased Bmi1 expression through miR-30e* suppression, leading to tumor progression (PMID:24312366)
• Results found that miR-30a* and miR-30e* were the top 2 significantly different miRNAs between type I and type II ovarian papillary serous carcinoma patients, and both were remarkably downregulated in the latter type. (PMID:24676806)
• Low MIR30E exprtession is asssociated with chronic myeloid leukemia. (PMID:25305453)
• High miR-30e expression is associated with glioma cell invasion. (PMID:25691332)
• miR-30e* was identified as independent protective prognostic factor in lymph node-negative untreated patients with ESR1+/ERBB2- tumours and retained a significant association with a good prognosis in treated patients (PMID:26057454)
• that serum miR-30e and miR-223 are useful biomarkers of hepatocellular carcinoma (PMID:26776075)
• data suggest that miR-30e functions in a cell type-dependent manner as an important molecular switch for DNA damage-induced stress responses (PMID:26895377)
• Thus, we conclude that miR-30e suppresses proliferation of hepatoma cells through targeting P4HA1 mRNA. (PMID:26966067)
• Suggest that reduced miR-30e correlates with the clinical stage of breast cancer. (PMID:27012041)
• AVEN and BIRC6 are inhibited by combination therapy of miR-30e and proanthocyanidin in glioblastoma stem cells (PMID:27388765)
• The hsa-miR-30e-5p, hsa-miR-92a-3p, and hsa-miR-223-3p are significantly up-regulated in plasma of systemic lupus erythematosus patients. (PMID:27596248)
• Data showed that miR-30e levels were markedly reduced in lung carcinoma samples and revealed that miR-30e amounts were even more reduced in gefitinib resistant cell lines. Interestingly, ectopic expression of miR-30e resulted in reduced cell proliferation, migration, induced apoptosis and sensitivity to gefitinib. (PMID:27992364)
• miR-30e in VSMCs exerted an anti-atherosclerosis effect via inhibiting proliferation and migration, and promoting apoptosis of VSMCs. More specifically, it was demonstrated that miR-30e exhibited these effects on VSMCs partially through targeting Ube2i and downregulating the IkappaBalpha/NFkappaB signaling pathway. (PMID:28123167)
• SOX2 regulates the proliferation, migration and invasiveness of breast cancer cells through miR-181a-5p and miR-30e-5p which modulate TUSC3 protein levels (PMID:28288641)
• miR-30e has a critical role in the suppression of hepatocellular carcinoma (HCC) and presents a novel mechanism of miRNA-mediated JAK1 expression in cancer cells that might be a good prognostic marker for survival of HCC patients. (PMID:28560434)
• MicroRNA-30e-5p promotes cell growth by targeting PTPN13 and indicates poor survival and recurrence in lung adenocarcinoma. (PMID:28653805)
• By directly binding to the 3’UTRs of ITGA6 and ITGB1, we found miR-30e-5p to suppress mainly the adhesion of ITGA6 in CRC cells to laminin.Taken together, miR-30e-5p is a novel effector of P53-induced suppression of migration, invasion and metastasis (PMID:28656629)
• Results show that miR-30e-5p induces NFAT5 expression by suppressing the MAP4K4 signaling pathway. Also, HBV inhibits NFAT5 through miR-30e-5p targeted MAP4K4, and miR-30e-5p in turn inhibits HBV replication. (PMID:29052520)
• miR-30e blocked the activation of AKT and ERK1/2 pathways, and the expression of HIF-1alpha and VEGF via directly targeting IRS1. (PMID:29162879)
• these findings suggest that miR-30e-5p suppresses non-small cell lung cancer (NSCLC) tumorigenesis by downregulating USP22-mediated Sirt1/JAK/STAT3 signaling. (PMID:29174979)
• early detection of plasma miRNA-30e level can be a preliminary assessment for risk of no-reflow during primary percutaneous coronary intervention. (PMID:29703083)
• T-96 might inhibit glioma cell growth by regulating the miR-30e-5p/MYBL2 axis. (PMID:30305611)
• miR-30e-5p negatively regulates mRNA and protein levels of USP22 by binding to its specific sequence of 3’UTR to inhibit proliferation and metastasis of nasopharyngeal carcinoma cells. (PMID:30338802)
• Up-regulated miR-30e can reduce the cytotoxicity of PB-NK cells and D-NK cells by targeting PRF1. (PMID:30551399)
• the level of plasma exosomal miR-30e and miR-92a was up-regulated in patients with atherosclerosis and negative correlate with the plasma cholesterol and ABCA1 level, which may provide a new biomarker for clinical diagnosis and treatment of coronary atherosclerosis. (PMID:30816508)
• Raised levels (>8) of miR-30e-5p at initial presentation in patients with ocular myasthenia gravis symptoms, give a predictive cut-off for subsequent generalization of 96-100% (PMID:30847357)
• miR-198 and miR-1183 were the two most significantly up-regulated microRNAs, and, miR-30e-5p and miR-144-3p were the two most significantly down-regulated microRNAs in Uyghur population with essential hypertension. (PMID:30975221)
• miR-30e-5p suppresses cell proliferation and migration in bladder cancer through regulating metadherin. (PMID:31069875)
• miR-30e was expressed at a low level in NSCLC tissues and cell lines. In NSCLC cell lines, enforced expression of miR-30e could inhibit cell proliferation and invasion in vitro. (PMID:31079325)
• Hsa-miR-30e expression was found to be significantly higher in patients with multiple gland disease compared to patients with single adenomas (p=0.0019), but no differences were found regarding specific genotype carriers. (PMID:31280217)
• Study found that miR-30e was correlated with the aggressive characteristics in patients with squamous cell carcinoma of the head and neck (SCCHN), which was an independent factor for prognosis in patients with SCCHN. miR-30e directly targeted oncogene AEG-1, impeding the invasion and metastasis of SCCHN via the modulation of both epithelial-mesenchymal transformation occurrence and cancer angiogenesis. (PMID:31778279)
• Long non-coding RNA DLEU2 promotes the progression of esophageal cancer through miR-30e-5p/E2F7 axis. (PMID:31884338)
• MiR-30e-3p Influences Tumor Phenotype through MDM2/TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. (PMID:32015093)
• CTHRC1 affects malignant tumor cell behavior and is regulated by miR-30e-5p in human prostate cancer. (PMID:32102754)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mir30d	ENSDARG00000081529
danio_rerio	mir30e-2	ENSDARG00000083500
danio_rerio	mir30a	ENSDARG00000090098

Paralogs (5): MIR30C2 (ENSG00000199094), MIR30D (ENSG00000199153), MIR30B (ENSG00000207582), MIR30A (ENSG00000207827), MIR30C1 (ENSG00000207962)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.